Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BBOX1 | O75936 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 2/20 | 0.37 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 4/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1616806 | 0.94 | — | — | |
| SCHEMBL22150642 | 0.94 | — | — | |
| SCHEMBL22115437 | 0.94 | BBOX1 (0.37) | BBOX1KDM4EMAPTALOX15SMN1; SMN2 | |
| Lithium Ion SCHEMBL18813428 | 0.94 | — | — | |
| Zinc Ion SCHEMBL377746 | 0.94 | BBOX1 (0.37) | BBOX1KDM4EMAPTALOX15SMN1; SMN2 | |
| Potassium Ion SCHEMBL156772 | 0.94 | — | — | |
| Hydrochloric Acid SCHEMBL4354105 | 0.91 | — | — | |
| Tetramethylammonium Ion SCHEMBL28756793 | 0.88 | BBOX1 (0.44) | BBOX1KDM4EMAPTALOX15SMN1; SMN2 | |
| Potassium Ion SCHEMBL434991 | 0.75 | BBOX1 (0.37) | BBOX1KDM4EMAPTALOX15SMN1; SMN2 | |
| SCHEMBL692963 | 0.75 | BBOX1 (0.37) | BBOX1KDM4EMAPTALOX15SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3674286-B1 | CONJUGATE ACID SALT OF N,N-DIMETHYLGLYCINE AND ORGANIC ACID, AND COMPOSITION AND APPLICATION THEREOF | GUANGZHOU INSIGHTER BIOTECHNOLOGY CO LTD (CN) | 2021-08-11 | — | — | EP | disclosed |
| US-10912749-B2 | Conjugate acid salt of N,N-dimethylglycine with organic acid, and composition and use thereof | Guangzhou Insighter Biotechnology Co., Ltd. (CN) | 2021-02-09 | — | — | US | disclosed |
| US-20200297675-A1 | CONJUGATE ACID SALT OF N,N-DIMETHYLGLYCINE WITH ORGANIC ACID, AND COMPOSITION AND USE THEREOF | Guangzhou Insighter Biotechnology Co., Ltd. (CN) | 2020-09-24 | — | — | US | disclosed |
| EP-3674286-A1 | CONJUGATE ACID SALT OF N,N-DIMETHYLGLYCINE AND ORGANIC ACID, AND COMPOSITION AND APPLICATION THEREOF | Guangzhou Insighter Biotechnology Co., Ltd. (CN) | 2020-07-01 | — | — | EP | disclosed |
| US-6043314-A | DIVALENT COPPER ION CROSSLINKING AGENT, POLYMER BEING PREPARED FROM MORE THAN ONE ETHYLENICALLY UNSATURATED MONOMER AND ACID CONTAININGFUNCTIONAL RESIDUES, | ROHM AND HAAS COMPANY (US) | 2000-03-28 | — | — | US | disclosed |
| EP-0943669-A1 | Process of improving the appearance of a floor polish composition | ROHM AND HAAS COMPANY (US) | 1999-09-22 | — | — | EP | disclosed |
| EP-0122788-B1 | SELF-LEVELING POLISH COMPOSITIONS AND POLYMER COMPOSITIONS USEFUL THEREIN | ROHM AND HAAS COMPANY (US) | 1987-09-23 | — | — | EP | disclosed |
| EP-0122788-A2 | Self-leveling polish compositions and polymer compositions useful therein | ROHM AND HAAS COMPANY (US) | 1984-10-24 | — | — | EP | disclosed |
| US-4460734-A | ETHYLENE OXIDE FATTY ALCOHOL ADDUCT, ADDITION POLYMER | ROHM AND HAAS COMPANY (US) | 1984-07-17 | — | — | US | disclosed |
| US-4145465-A | CROSSLINKED ADDITION POLYMER | ROHM AND HAAS COMPANY (US) | 1979-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200297675-A1 | CONJUGATE ACID SALT OF N,N-DIMETHYLGLYCINE WITH ORGANIC ACID, AND COMPOSITION AND USE THEREOF | SLC7A1, SLC7A5, SLC6A15 | BBOX1 1650/4885KDM4E 4317/4885MAPT 895/4885 |
| US-10912749-B2 | Conjugate acid salt of N,N-dimethylglycine with organic acid, and composition and use thereof | SLC7A1, SLC7A5, SLC6A15 | BBOX1 1650/4885KDM4E 4317/4885MAPT 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.